See more : Canadian Utilities Limited 2ND PFD SER Y (CNAUF) Income Statement Analysis – Financial Results
Complete financial analysis of Monte Rosa Therapeutics, Inc. (GLUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monte Rosa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- LAND Co., Ltd. (8918.T) Income Statement Analysis – Financial Results
- Speciality Restaurants Limited (SPECIALITY.NS) Income Statement Analysis – Financial Results
- Cascade Acquisition Corp. (CAS) Income Statement Analysis – Financial Results
- China Internet Investment Finance Holdings Limited (0810.HK) Income Statement Analysis – Financial Results
- ACWA POWER Company (2082.SR) Income Statement Analysis – Financial Results
Monte Rosa Therapeutics, Inc. (GLUE)
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| Gross Profit | -6.22M | -8.56M | -2.13M | -537.00K | -72.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 111.27M | 85.06M | 57.16M | 24.01M | 7.35M |
| General & Administrative | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Other Expenses | 0.00 | 0.00 | -960.00K | -7.68M | 276.00K |
| Operating Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Cost & Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Interest Income | 9.33M | 3.76M | 46.00K | 9.00K | 12.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 0.00 | 1.00K |
| Depreciation & Amortization | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| EBITDA | -137.09M | -99.94M | -70.75M | -27.47M | -7.67M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.31M | -112.38M | -72.88M | -28.01M | -7.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 3.88M | -1.08M | -7.87M | 254.00K |
| Income Before Tax | -135.01M | -108.50M | -73.96M | -35.88M | -7.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 338.00K | -3.88M | -2.02M | 189.00K | 277.00K |
| Net Income | -135.35M | -104.62M | -71.94M | -36.07M | -8.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Avg Shares Out | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| Weighted Avg Shares Out (Dil) | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; determination of recommended Phase 2 dose expected in Q2 2024; Phase 1 clinical data anticipated in H2 2024 MRT-6160, a VAV1-directed...
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer
BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D.
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why
Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?
The consensus price target hints at a 107.8% upside potential for Monte Rosa Therapeutics (GLUE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why
Monte Rosa Therapeutics (GLUE) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price...
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know
The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to an 117.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an...
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 MRT-6160, a VAV1-directed MGD designed to treat...
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
MRT-8102 nominated as first NEK7-directed development candidate, targeting inflammatory diseases driven by IL-1β and the NLRP3 inflammasome MRT-8102 and other NEK7 program MGDs are potentially applicable across a range of inflammatory disorders, metabolic disorders, as well as ocular and neurological...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim 6th Annual Biotechnology Conference (New...
Source: https://incomestatements.info
Category: Stock Reports